Logo image of BRZE

BRAZE INC-A (BRZE) Stock Fundamental Analysis

NASDAQ:BRZE - Nasdaq - US10576N1028 - Common Stock - Currency: USD

26.85  +0.21 (+0.79%)

Fundamental Rating

4

BRZE gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 282 industry peers in the Software industry. The financial health of BRZE is average, but there are quite some concerns on its profitability. BRZE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BRZE was profitable.
In the past year BRZE had a positive cash flow from operations.
In the past 5 years BRZE always reported negative net income.
In multiple years BRZE reported negative operating cash flow during the last 5 years.
BRZE Yearly Net Income VS EBIT VS OCF VS FCFBRZE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -11.68%, BRZE is doing worse than 61.35% of the companies in the same industry.
BRZE has a Return On Equity (-21.90%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -11.68%
ROE -21.9%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-15.52%
ROE(3y)-27.38%
ROE(5y)-29.17%
ROIC(3y)N/A
ROIC(5y)N/A
BRZE Yearly ROA, ROE, ROICBRZE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40

1.3 Margins

The Gross Margin of BRZE (69.44%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of BRZE has grown nicely.
BRZE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.04%
GM growth 5Y1.88%
BRZE Yearly Profit, Operating, Gross MarginsBRZE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

6

2. Health

2.1 Basic Checks

BRZE does not have a ROIC to compare to the WACC, probably because it is not profitable.
BRZE has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BRZE has been increased compared to 5 years ago.
BRZE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BRZE Yearly Shares OutstandingBRZE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
BRZE Yearly Total Debt VS Total AssetsBRZE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 3.80 indicates that BRZE is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 3.80, BRZE is doing good in the industry, outperforming 63.12% of the companies in the same industry.
There is no outstanding debt for BRZE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.8
ROIC/WACCN/A
WACC10.76%
BRZE Yearly LT Debt VS Equity VS FCFBRZE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 1.92 indicates that BRZE should not have too much problems paying its short term obligations.
With a Current ratio value of 1.92, BRZE perfoms like the industry average, outperforming 59.57% of the companies in the same industry.
A Quick Ratio of 1.92 indicates that BRZE should not have too much problems paying its short term obligations.
BRZE has a Quick ratio of 1.92. This is comparable to the rest of the industry: BRZE outperforms 59.93% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
BRZE Yearly Current Assets VS Current LiabilitesBRZE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

BRZE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 266.67%, which is quite impressive.
The Revenue has grown by 22.66% in the past year. This is a very strong growth!
The Revenue has been growing by 43.83% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)266.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%240%
Revenue 1Y (TTM)22.66%
Revenue growth 3Y35.6%
Revenue growth 5Y43.83%
Sales Q2Q%19.64%

3.2 Future

The Earnings Per Share is expected to grow by 55.41% on average over the next years. This is a very strong growth
Based on estimates for the next years, BRZE will show a quite strong growth in Revenue. The Revenue will grow by 17.40% on average per year.
EPS Next Y-1.91%
EPS Next 2Y43.75%
EPS Next 3Y60.31%
EPS Next 5Y55.41%
Revenue Next Year19.51%
Revenue Next 2Y18.14%
Revenue Next 3Y18%
Revenue Next 5Y17.4%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BRZE Yearly Revenue VS EstimatesBRZE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
BRZE Yearly EPS VS EstimatesBRZE Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 89.50, which means the current valuation is very expensive for BRZE.
Compared to the rest of the industry, the Price/Earnings ratio of BRZE is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 27.18, BRZE is valued quite expensively.
BRZE is valuated quite expensively with a Price/Forward Earnings ratio of 72.19.
BRZE's Price/Forward Earnings ratio is in line with the industry average.
BRZE's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 35.34.
Industry RankSector Rank
PE 89.5
Fwd PE 72.19
BRZE Price Earnings VS Forward Price EarningsBRZE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

BRZE's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 91.29
EV/EBITDA N/A
BRZE Per share dataBRZE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

BRZE's earnings are expected to grow with 60.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.75%
EPS Next 3Y60.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BRZE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRAZE INC-A

NASDAQ:BRZE (7/16/2025, 1:44:59 PM)

26.85

+0.21 (+0.79%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)06-05 2025-06-05/amc
Earnings (Next)09-01 2025-09-01/amc
Inst Owners77.21%
Inst Owner Change0%
Ins Owners3.39%
Ins Owner Change1.61%
Market Cap2.84B
Analysts83.85
Price Target46.28 (72.36%)
Short Float %6.41%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)87.99%
Min EPS beat(2)50.17%
Max EPS beat(2)125.81%
EPS beat(4)4
Avg EPS beat(4)268.44%
Min EPS beat(4)50.17%
Max EPS beat(4)523.5%
EPS beat(8)8
Avg EPS beat(8)159.72%
EPS beat(12)12
Avg EPS beat(12)115.87%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.56%
Min Revenue beat(2)0.14%
Max Revenue beat(2)0.98%
Revenue beat(4)4
Avg Revenue beat(4)0.67%
Min Revenue beat(4)0.14%
Max Revenue beat(4)0.98%
Revenue beat(8)8
Avg Revenue beat(8)1.73%
Revenue beat(12)12
Avg Revenue beat(12)1.72%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.11%
PT rev (3m)-14.74%
EPS NQ rev (1m)-31.6%
EPS NQ rev (3m)-64.72%
EPS NY rev (1m)-48.92%
EPS NY rev (3m)-39.3%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)1.33%
Revenue NY rev (1m)1.93%
Revenue NY rev (3m)2.57%
Valuation
Industry RankSector Rank
PE 89.5
Fwd PE 72.19
P/S 4.57
P/FCF 91.29
P/OCF 68.45
P/B 5.98
P/tB 6.4
EV/EBITDA N/A
EPS(TTM)0.3
EY1.12%
EPS(NY)0.37
Fwd EY1.39%
FCF(TTM)0.29
FCFY1.1%
OCF(TTM)0.39
OCFY1.46%
SpS5.87
BVpS4.49
TBVpS4.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.68%
ROE -21.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.44%
FCFM 5.01%
ROA(3y)-15.85%
ROA(5y)-15.52%
ROE(3y)-27.38%
ROE(5y)-29.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.04%
GM growth 5Y1.88%
F-Score6
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 97.84%
Cap/Sales 1.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z 3.8
F-Score6
WACC10.76%
ROIC/WACCN/A
Cap/Depr(3y)240.58%
Cap/Depr(5y)230.69%
Cap/Sales(3y)3.47%
Cap/Sales(5y)3.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)266.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%240%
EPS Next Y-1.91%
EPS Next 2Y43.75%
EPS Next 3Y60.31%
EPS Next 5Y55.41%
Revenue 1Y (TTM)22.66%
Revenue growth 3Y35.6%
Revenue growth 5Y43.83%
Sales Q2Q%19.64%
Revenue Next Year19.51%
Revenue Next 2Y18.14%
Revenue Next 3Y18%
Revenue Next 5Y17.4%
EBIT growth 1Y21.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year755.76%
EBIT Next 3Y184.55%
EBIT Next 5Y120.88%
FCF growth 1Y194.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y334.33%
OCF growth 3YN/A
OCF growth 5YN/A